PMV Pharmaceuticals (PMVP) investor relations material

Executive summary

• Focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations, with lead candidate rezatapopt in pivotal Phase 2 trials and recent Orphan Drug Designation for ovarian, fallopian tube, and primary peritoneal cancers; Fast Track status for advanced solid tumors.

• First-in-human data published in the New England Journal of Medicine demonstrated selective reactivation of mutant p53 in advanced solid tumors.

• NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027.

• No product revenue to date; operations funded by equity issuances and marketable securities.

• Net loss of $18.0 million for Q1 2026, with accumulated deficit reaching $464.5 million.

Financial highlights

• Q1 2026 net loss: $18.0 million, compared to $17.4 million in Q1 2025.

• Operating expenses decreased to $19.0 million from $21.6 million year-over-year, driven by lower R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $93.5 million as of March 31, 2026, down from $112.9 million at December 31, 2025.

• No revenue generated; interest income declined to $1.0 million from $1.9 million year-over-year.

• Cash runway expected to last through the end of Q2 2027.

Outlook and guidance

• Cash runway expected to fund operations through Q2 2027 based on current plans.

• Plans to submit NDA for rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027.

• Enrollment in the Phase 2 PYNNACLE monotherapy trial is on track.

• Anticipates continued significant operating losses as clinical development progresses.